EUVIMEDEUVIMED entdecken
Open Access

Case Series: Magnitude and duration of fentanyl and xylazine detection in the urine of persons with opioid use disorder

Helen E Bird, William A Clarke, Craig W Hendrix, Kelly E Dunn, Andrew S Huhn

The American Journal on Addictions · 2025

DOI: 10.1111/ajad.70015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The American Journal on Addictions, 2025. Verfasst von Helen E Bird und 4 weiteren Autor:innen. Beteiligte Einrichtung: Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Mary…. Hauptthemen laut MEDLINE: Analgesics, Opioid, Fentanyl, Opioid-Related Disorders, Xylazine. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NIDA NIH HHS, National Institute on Drug Abuse.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives The pharmacology of fentanyl and xylazine is not characterized in persons regularly exposed to illicit fentanyl. This case series presents individual‐level urine pharmacokinetics of fentanyl, norfentanyl, and xylazine in persons with opioid use disorder (OUD).

Methods

Participants ( N = 11) provided urine samples ( n = 95) for quantitative analysis. Terminal half‐lives and predicted detection times were calculated.

Results

Urinary half‐life ranges were: fentanyl 1.5–28.7 h, norfentanyl 5.2–27.4 h, and xylazine 1.1–25.2 h. Predicted detection window ranges were: fentanyl 13.0–130.9 h (0.5–5.5 days), norfentanyl 64.8–255.9 h (2.7–10.7 days), and xylazine 13.8–123.4 h (0.6–5.1 days). Discussion/Conclusions Persons are presenting with a high magnitude of drug exposure that lends to an extended duration of urinary detection. Significance First characterization of urinary excretion in persons with OUD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Analgesics, OpioidFentanylOpioid-Related DisordersXylazineAdultFemaleHumansMaleMiddle AgedHalf-LifeSubstance Abuse Detection

Substanzen

Analgesics, OpioidFentanylnorfentanylXylazine

Autor:innen und Institutionen

  • Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Division of Clinical Pharmacology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Division of Clinical Chemistry, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Förderung

  • NIGMS NIH HHS
  • NIDA NIH HHS
  • National Institute on Drug Abuse
  • National Institute of General Medical Sciences

Zitieren

APA

Bird, H. E., Clarke, W. A., Hendrix, C. W., Dunn, K. E., & Huhn, A. S. (2025). Case Series: Magnitude and duration of fentanyl and xylazine detection in the urine of persons with opioid use disorder. The American Journal on Addictions. https://doi.org/10.1111/ajad.70015

Vancouver

Bird HE, Clarke WA, Hendrix CW, Dunn KE, Huhn AS. Case Series: Magnitude and duration of fentanyl and xylazine detection in the urine of persons with opioid use disorder. The American Journal on Addictions. 2025. doi:10.1111/ajad.70015

BibTeX
@article{Bird2025,
  author = {Bird, Helen E and Clarke, William A and Hendrix, Craig W and Dunn, Kelly E and Huhn, Andrew S},
  title = {Case Series: Magnitude and duration of fentanyl and xylazine detection in the urine of persons with opioid use disorder},
  journal = {The American Journal on Addictions},
  year = {2025},
  doi = {10.1111/ajad.70015}
}
Kostenlos starten →